{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02566655",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CSM/OP/2011"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2012-005814-20",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Red de Terapia Celular",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis",
      "OfficialTitle": "Phase I Clinical Trial To Evaluate The Intravenous Infusion Of Autologous Fucosylated Bone Marrow Mesenchymal Cells Therapy In Patients With Established Osteoporosis and Low Impact Fractures",
      "Acronym": "CSM/OP/2011"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2019",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "September 2015"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2016",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "May 2018",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "January 30, 2015",
      "StudyFirstSubmitQCDate": "September 30, 2015",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 2, 2015",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "October 7, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "October 8, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Red de Terapia Celular",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Hospital Universitario Virgen de la Arrixaca",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Spanish National Health System",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Public Health Service, Murcia",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "BIONAND, Universidad de Málaga, IBIMA, Ciber-bbn",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Grupo de Tecnología Sanitaria CIBER-BBN, Inst. Biomecánica de Valencia",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the safety of intravenous infusion of fucosylated autologous bone marrow cells as a new therapy in patients with established osteoporosis by a prospective, single-center, open, non-randomized and unblinded clinical trial."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Osteoporosis",
          "Spinal Fractures"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "10",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Fucosylated MSC for Osteoporosis",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Autologous Bone Marrow fucosylated mesenchymal stem cells will be infused intravenously on Day 0. The first four patients enrolled will receive a single dose of 2 million cells/Kg and the last six patients enrolled, will receive a single dose of 5 million cells/kg.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Fucosylated MSC for Osteoporosis"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Fucosylated MSC for Osteoporosis",
            "InterventionDescription": "Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).\n\nMononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Fucosylated MSC for Osteoporosis"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Rate of serious and non-serious adverse events related to the procedure.",
            "PrimaryOutcomeDescription": "During time frame the following items will be considered:\n\nAdverse effects related to the infusion moment. Occurrence of infectious complications after infusion of mesenchymal stem cells, because of the immunosuppressive effect of these cells.\n\nAppearance of procedure-related neoplasias.",
            "PrimaryOutcomeTimeFrame": "24 months from baseline"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Number of new fractures",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Pain, measured by Visual Analog Scale",
            "SecondaryOutcomeDescription": "To measure pain, visual analogue scale (VAS) was used where 0 is no pain and 10 the worst pain imaginable.",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Functionality, measured by Oswestry Disability Questionnaire",
            "SecondaryOutcomeDescription": "To identify the functional repercussion of lumbar pain, Oswestry Disability Questionnaire for back pain or Oswestry Disability Index is used.",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Quality of Life, measured by EuroQoL-5D test",
            "SecondaryOutcomeDescription": "To measure the quality of life EuroQoL-5D psychometric test is used.",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Bone resorption, measured by biochemical index",
            "SecondaryOutcomeDescription": "Aminoterminal telopeptide of type 1 collagen in the serum (serum NTX) (%) by ELISA technique.",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Bone formation, measured by biochemical index",
            "SecondaryOutcomeDescription": "Osteocalcin in the serum by ELISA (BPG serum) (ng / mL) .",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Bone formation, measured by biochemical index",
            "SecondaryOutcomeDescription": "Bone specific alkaline phosphatase in the serum by ELISA (serum FAO) (ug / L)",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Bone formation, measured by biochemical index",
            "SecondaryOutcomeDescription": "Aminoterminal propeptide of procollagen type 1 in the serum by ELISA (serum P1NP) (ng / mL)",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Bone metabolism, measured by biochemical index",
            "SecondaryOutcomeDescription": "Osteoprotegerin (OPG) (pmol / L) in the serum by ELISA.",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Bone metabolism, measured by biochemical index",
            "SecondaryOutcomeDescription": "Ligand receptor activator of nuclear factor KB (RANKL) (pmol / L) in the serum by ELISA.",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Bone Mineral Density , measured by dual energy x-ray absorptiometry (DXA)",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Bone structure, measured by histomorphometric evaluation",
            "SecondaryOutcomeTimeFrame": "baseline and 4 months from baseline"
          },
          {
            "SecondaryOutcomeMeasure": "Trabecular bone density measured by quantitative computed tomography of the radius",
            "SecondaryOutcomeTimeFrame": "24 months from baseline"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients with established osteoporosis according to standard clinical criteria.\nPatients who give their written informed consent to participate in the study consent.\nMeet all the inclusion criteria\n\nExclusion Criteria:\n\nPatients with concomitant systemic disease in the opinion of the investigator.\nPatients with rheumatoid arthritis, ankylosing spondylitis, chronic polyarticular arthritis.\nCurrent patients with neoplasm or history of any malignancy in the last 10 years except basal carcinoma or epidermoid skin.\nPatients with genetic disorders that are associated with secondary osteoporosis: Hemochromatosis, hypophosphatasia, osteogenesis imperfecta, Ehlers-Danlos syndrome, Marfan syndrome, Riley Day, porphyria, storage diseases syndrome.\nPatients receiving immunosuppressive chemotherapy or that could interfere with the process of cell proliferation.\nTransplant patients: bone marrow, kidney, liver, heart, lung.\nPatients with clinical criteria and anesthetics that contraindicate well sedation or bone marrow extraction.\nPatients participating in a clinical trial in the last 6 months.\nPatients with positive serology for hepatitis B, hepatitis C or HIV.\nPatients with inability to understand informed consent.\nPatients who are pregnant or breast-feeding actively.\nPatients physically fertile, defined as all women physiologically capable of becoming pregnant, UNLESS they are using reliable methods of contraception.",
      "HealthyVolunteers": "No",
      "Gender": "Female",
      "MinimumAge": "50 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Luis F Linares Ferrando, MD",
            "OverallOfficialAffiliation": "Hospital Universitario Virgen de la Arrixaca",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Hospital Clínico Virgen de la Arrixaca",
            "LocationCity": "El Palmar",
            "LocationState": "Murcia",
            "LocationZip": "30120",
            "LocationCountry": "Spain"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000010024",
            "ConditionMeshTerm": "Osteoporosis"
          },
          {
            "ConditionMeshId": "D000016103",
            "ConditionMeshTerm": "Spinal Fractures"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000050723",
            "ConditionAncestorTerm": "Fractures, Bone"
          },
          {
            "ConditionAncestorId": "D000014947",
            "ConditionAncestorTerm": "Wounds and Injuries"
          },
          {
            "ConditionAncestorId": "D000001851",
            "ConditionAncestorTerm": "Bone Diseases, Metabolic"
          },
          {
            "ConditionAncestorId": "D000001847",
            "ConditionAncestorTerm": "Bone Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          },
          {
            "ConditionAncestorId": "D000013124",
            "ConditionAncestorTerm": "Spinal Injuries"
          },
          {
            "ConditionAncestorId": "D000019567",
            "ConditionAncestorTerm": "Back Injuries"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M25523",
            "ConditionBrowseLeafName": "Fractures, Bone",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12099",
            "ConditionBrowseLeafName": "Osteoporosis",
            "ConditionBrowseLeafAsFound": "Osteoporosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M17733",
            "ConditionBrowseLeafName": "Spinal Fractures",
            "ConditionBrowseLeafAsFound": "Spinal Fractures",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M16837",
            "ConditionBrowseLeafName": "Wounds and Injuries",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4282",
            "ConditionBrowseLeafName": "Bone Diseases, Metabolic",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4278",
            "ConditionBrowseLeafName": "Bone Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M15073",
            "ConditionBrowseLeafName": "Spinal Injuries",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20656",
            "ConditionBrowseLeafName": "Back Injuries",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC26",
            "ConditionBrowseBranchName": "Wounds and Injuries"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          }
        ]
      }
    }
  }
}